Profit Over Patient Lives: How One Price Hike Turned a $13 Cancer Drug Into a $1,200 Monthly Sentence

A single pill, chalky and unremarkable, once sold for roughly the price of a sandwich. Patients swallowed it without ceremony. Then, almost overnight, the same pill began to cost more than a month’s rent.

The jump—from about $13 to more than $1,200 for a typical month’s supply—didn’t happen because scientists discovered a miraculous new benefit or because manufacturing costs exploded. It happened because a company realized it could. And for cancer patients already fighting for their lives, that decision landed like a sentence handed down without appeal.

The Drug That Changed but Didn’t Improve

The medication at the center of this story is lomustine, also known by its brand name CCNU. Oncologists have prescribed it for decades to treat brain tumors, including glioblastoma, one of the deadliest cancers known. Lomustine isn’t experimental. It isn’t cutting-edge. The National Cancer Institute lists it as an “essential medicine” for specific regimens.

For years, a dose cost somewhere in the low double digits. In 2013, after the drug changed hands between manufacturers, the price per capsule jumped dramatically—reports by ProPublica and STAT documented increases of more than 1,400 percent in some cases. Depending on the dosing schedule, patients saw monthly costs soar past $1,200.

No new trials justified the increase. No reformulation improved outcomes. The only thing that changed was ownership.

That distinction matters. Drug companies often defend high prices by pointing to research and development costs. Lomustine had already paid those debts decades ago. The price hike reflected market power, not medical progress.

“I Thought There Was a Billing Error”

Linda W., a retired school librarian from Ohio, learned about the increase while recovering from brain surgery in 2014. Her oncologist prescribed lomustine as part of a standard chemotherapy protocol. Linda’s husband drove to the pharmacy expecting a routine pickup.

“The pharmacist pulled him aside and whispered the price,” Linda recalled in an interview cited by STAT. “I thought there was a billing error. We had good insurance. We’d never paid more than a few hundred dollars for anything.”

Their insurer covered part of the cost, but the copay alone exceeded $400 per month. Linda and her husband lived on a fixed income. They cut back on groceries, delayed home repairs, and drained savings meant for retirement. “You don’t tell your doctor you can’t afford the drug that might keep you alive,” she said. “You just figure it out.”

Not everyone can.

A 2019 study in JAMA Oncology found that cancer patients are 2.5 times more likely to declare bankruptcy than people without cancer. High drug prices play a central role. Bankruptcy, in turn, correlates with higher mortality rates—patients under severe financial stress are less likely to adhere to treatment, more likely to skip doses, and more likely to abandon care altogether.

The Public Health Cost of a Private Decision

Lomustine’s price hike rippled far beyond individual households. Hospitals faced shortages as budgets strained. Some oncology centers began rationing the drug or substituting less effective alternatives. Others delayed treatment while administrators negotiated with suppliers.

Public health systems felt the shock too. Medicare Part D spending on oncology drugs has climbed steadily, reaching more than $50 billion annually by 2022, according to the Centers for Medicare & Medicaid Services. While lomustine represents a small slice of that total, its story mirrors a broader pattern: older generics with no competition become cash machines.

Economist Aaron Kesselheim of Harvard Medical School has studied this phenomenon extensively. His research shows that when a single manufacturer controls a generic drug with low demand, prices can skyrocket with little regulatory resistance. “The market is functioning exactly as designed,” Kesselheim told Congress in 2016. “The problem is that the design ignores patients.”

Why Competition Never Came

In theory, generic drugs invite competition. In practice, cancer drugs like lomustine face barriers that deter new entrants:

• Tiny patient populations. Glioblastoma affects about 12,000 Americans each year. That limits potential revenue.
• Complex manufacturing. Chemotherapy agents require specialized facilities and strict safety protocols.
• Regulatory friction. Gaining FDA approval for a generic can take years, even for decades-old drugs.

The result: monopolies hiding in plain sight.

When one company controls supply, it controls price. Hospitals can’t easily shop around. Patients can’t substitute another medication without risking survival. The usual market checks fail.

The Ethics of Pricing a Lifeline

Drug pricing debates often drift into abstraction—percentages, pipelines, shareholder returns. Lomustine drags the conversation back to earth.

Should a company be allowed to raise the price of an essential cancer drug by more than tenfold without improving it? Should public insurers pay whatever price the market sets, even when taxpayers foot the bill? Should patients bear financial toxicity as a side effect of treatment?

Pharmaceutical executives argue they operate within the law. They’re right. But legality doesn’t equal legitimacy.

A 2021 survey by the Kaiser Family Foundation found that 83 percent of Americans believe prescription drug prices are unreasonable. Among cancer patients, the sentiment runs hotter. Many describe feeling exploited at their most vulnerable moment.

What Patients Can Do Right Now

Structural reform moves slowly. Patients need tools today. Oncologists and advocates point to several practical steps that can blunt the impact of price hikes:

• Request insurer exceptions. Many plans will lower copays for essential cancer drugs if physicians document medical necessity.
• Use independent drug price comparison tools. Services like GoodRx Gold Prescription Savings Card and RxSaver Prescription Discount Program sometimes negotiate lower cash prices than insurance copays.

• Contact nonprofit assistance programs. Organizations such as the Patient Advocate Foundation and CancerCare offer direct financial aid for medication costs.
• Ask about compounding pharmacies. In rare cases, licensed compounding pharmacies can prepare equivalent formulations at lower cost, though availability varies.

None of these fixes the system. All can buy time.

The Policy Levers That Actually Matter

Washington has taken tentative steps. The Inflation Reduction Act of 2022 granted Medicare limited authority to negotiate prices for a small number of high-cost drugs starting in 2026. Lomustine isn’t on the initial list. Many older generics won’t be.

Experts argue that Congress must go further:

• Automatic price review triggers when essential generics spike beyond a defined threshold.
• Temporary manufacturing licenses allowing additional producers to enter the market during price emergencies.
• Transparency requirements forcing companies to justify increases on off-patent drugs.

Countries like Germany and Canada already use versions of these tools. Their cancer patients pay a fraction of what Americans do for the same medicines.

The Human Ledger

Lomustine didn’t cure Linda W.’s cancer. It bought her time—enough to attend her granddaughter’s high school graduation, enough to put her affairs in order. She doesn’t regret taking it. She resents the price.

“I wasn’t asking for a miracle,” she said. “I was asking not to be punished for getting sick.”

Her words cut through the noise. When a $13 drug becomes a $1,200 monthly sentence, the debate stops being about markets and starts being about values. The question isn’t whether the system allows it. The question is why we do.